The findings revealed a potential mechanism of TKI resistance via the NAT10-ac4C-FATP4-CPT1A axis and indicated that targeting NAT10 with Remodelin may effectively address clinical EGFR-TKI resistance in NSCLC. Here, NAT10 is linked to non-small cell lung carcinoma.